TerrAscend (OTCMKTS:TSNDF) and GE HealthCare Technologies (NASDAQ:GEHC) Head-To-Head Review

TerrAscend (OTCMKTS:TSNDF) and GE HealthCare Technologies (NASDAQ:GEHC) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, risk, profitability, analyst recommendations, valuation, earnings and dividends.

Earnings and Valuation

This table compares TerrAscend and GE HealthCare Technologies”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TerrAscend	$260.56 million	0.81	-$81.33 million	($0.11)	-6.20
GE HealthCare Technologies	$20.62 billion	1.45	$2.08 billion	$4.36	15.16

GE HealthCare Technologies has higher revenue and earnings than TerrAscend. TerrAscend is trading at a lower price-to-earnings ratio than GE HealthCare Technologies, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and target prices for TerrAscend and GE HealthCare Technologies, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TerrAscend	0	1	0	1	3.00
GE HealthCare Technologies	0	11	11	0	2.50

GE HealthCare Technologies has a consensus target price of $78.39, suggesting a potential upside of 18.61%. Given GE HealthCare Technologies’ higher possible upside, analysts plainly believe GE HealthCare Technologies is more favorable than TerrAscend.

Profitability

This table compares TerrAscend and GE HealthCare Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
TerrAscend	-31.01%	-32.93%	-5.49%
GE HealthCare Technologies	9.33%	20.12%	5.74%

Insider & Institutional Ownership

5.8% of TerrAscend shares are held by institutional investors. Comparatively, 82.1% of GE HealthCare Technologies shares are held by institutional investors. 31.9% of TerrAscend shares are held by insiders. Comparatively, 0.4% of GE HealthCare Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

TerrAscend has a beta of 1.44, meaning that its share price is 44% more volatile than the S&P 500. Comparatively, GE HealthCare Technologies has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500.

Summary

GE HealthCare Technologies beats TerrAscend on 11 of the 15 factors compared between the two stocks.

About TerrAscend

TerrAscend Corp. cultivates, processes, and sells medical and adult use cannabis in Canada and the United States. The company produces and distributes hemp-derived wellness products to retail locations; and manufactures vaporizables, concentrates, topicals, tinctures and edibles. It also operates retail dispensaries under the Apothecarium and State Flower brand names. The company was incorporated in 2017 and is headquartered in Mississauga, Canada.

About GE HealthCare Technologies

GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, X-ray systems, and women’s health products. The Ultrasound segment provides medical devices and solutions for screening, diagnosis, treatment, and monitoring of certain diseases in clinical areas, such as radiology and primary care, women’s health, cardiovascular, and point of care and handheld ultrasound solutions, as well as surgical visualization and guidance products. The Patient Care Solutions segment provides medical devices, consumables, services, and digital solutions. Its portfolio includes patient monitoring solutions, anesthesia delivery and respiratory care products, electrocardiogram solutions, maternal infant care products, and consumables and services. The Pharmaceutical Diagnostics supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, positron emission tomography, and ultrasound to the radiology and nuclear medicine industry. The segment also provides contrast media pharmaceuticals that are administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes. It has an AI collaboration with Mass General Brigham. The company was formerly known as GE Healthcare Holding LLC and changed its name to GE HealthCare Technologies Inc. in December 2022. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.